Brief: FDA Grants Seastar Medical Two New Breakthrough Device Designations For Scd Therapy
08/04/2025 14:33
April 8 (Reuters) - SeaStar Medical Holding Corp ICU.O: FDA GRANTS SEASTAR MEDICAL TWO NEW BREAKTHROUGH DEVICE DESIGNATIONS FOR SCD THERAPY TO TREAT SYSTEMIC INFLAMMATORY RESPONSE IN ADULT AND PEDIATRIC PATIENTS UNDERGOING CARDIAC SURGERY Source text: ID:nGNX519sSz Further company coverage: ICU.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on SeaStar Medical Holding
See all newsBrief: FDA Grants Seastar Medical Breakthrough Device Designation For Its Scd Therapy For The Treatment Of Hyperinflammation In Adult Patients With Sepsis Or A Septic Condition
SeaStar Medical Holding Corp reports results for the quarter ended June 30 - Earnings Summary
SeaStar Medical Q2 revenue jumps 82% on QUELIMMUNE demand
Brief: SeaStar Medical Q2 EPS USD -0.91
SeaStar Medical Holding Corp expected to post a loss of 97 cents a share - Earnings Preview